Skip to main content

GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales

London-based GSK is preparing to roll out its RSV vaccine in the U.S. and European Union this fall, when the disease begins to spread at higher levels.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.